People · Operator
Named in public records as an officer, director or promoter · active 2011–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Hapten Sciences, Inc. | — | Pharmaceuticals | Seed | $10.5M | $64.1M | 2011 |
| Focal Point Pharmaceuticals, Inc. | — | Pharmaceuticals | Pre-Seed | $150K | $7.1M | 2013 |
Gary Prosterman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gary Prosterman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gary L. Stevenson | 1 | 2 |
| Raymond J Hage | 1 | 2 |
| Gary I. Stevenson | 1 | 1 |
| Stephen I. Bandak | 1 | 1 |
| Joseph I. Zakrzewski | 1 | 1 |
| Stephen L. Bandak | 1 | 1 |
| Joseph L. Zakrzewski | 1 | 1 |
| Raymond Hage | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.